Allink Biotherapeutics

Allink Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation bispecific antibodies and antibody-drug conjugates (ADCs) for oncology and immunology. Founded in 2023 by industry veteran Dr. Hui Feng, the company leverages its proprietary technology platforms to engineer high-drug-to-antibody ratio (DAR) and hydrophilic ADC candidates with optimized therapeutic windows. Its lead program, ALK201, is a potential first-in-class FGFR2b-targeted ADC currently in Phase 1 clinical trials for advanced solid tumors. Additionally, Allink is advancing ALK202, a bispecific ADC targeting both EGFR and cMET, designed to overcome resistance mechanisms in lung cancer and other malignancies. The company is headquartered in Shanghai and supported by a syndicate of top-tier venture capital investors.